Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Hepatology

• Publication date

  2007-09-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.21940PMID 17886336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Complications of Cirrhosis

  2008cited by this paper
• Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

  2007cited by this paper
• Role of endothelin and endothelin receptor antagonists in renal disease

  2006cited by this paper
• Hepatorenal syndrome.

  2006cited by this paper
• The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure

  2004cited by this paper
• Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans.

  2004cited by this paper
• Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats

  2004cited by this paper
• Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock

  2004cited by this paper
• RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.

  2003cited by this paper
• Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry.

  2003cited by this paper
• Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide

  2003cited by this paper
• Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.

  2003cited by this paper
• Systemic and regional changes in plasma endothelin following transient increase in portal pressure

  2003cited by this paper
• Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).

  2003cited by this paper
• Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation

  2003cited by this paper
• The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club

  2003cited by this paper
• Hepatorenal syndrome.

  2003cited by this paper
• Endothelin receptor antagonists: structures, synthesis, selectivity and therapeutic applications.

  2002cited by this paper
• Role of endothelin-1 in a cirrhotic rat model with endotoxin induced acute renal failure.

  2002cited by this paper
• Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.

  2002cited by this paper
• Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure

  2002cited by this paper
• Hepatorenal syndrome in cirrhosis: pathogenesis and treatment.

  2002cited by this paper
• Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology — WARIS II, ESCAMI, PAFAC, RITZ‐1 and TIME

  2001cited by this paper
• Endothelin Mediates the Altered Renal Hemodynamics Associated with Experimental Congestive Heart Failure

  2001cited by this paper
• The intrarenal endothelin system and hypertension.

  2001cited by this paper
• THE USE OF THE ENDOTHELIN RECEPTOR ANTAGONIST, TEZOSENTAN, BEFORE OR AFTER RENAL ISCHEMIA PROTECTS RENAL FUNCTION1

  2001cited by this paper
• Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation

  2000cited by this paper
• Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.

  2000cited by this paper
• Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use.

  1999cited by this paper
• Measurement of plasma renin activity with use of HPLC-electrospray-tandem mass spectrometry.

  1999cited by this paper
• Rapid determination of p-aminohippuric acid in serum and urine by high-performance liquid chromatography.

  1997cited by this paper
• Amelioration of hepatorenal syndrome with selective endothelin-A antagonist.

  1996cited by this paper
• Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems.

  1996cited by this paper
• Role of endothelin in acute renal failure due to rhabdomyolysis in rats.

  1995cited by this paper
• Endothelins.

  1995cited by this paper
• Endothelin‐1 and ‐3 plasma concentrations in patients with cirrhosis: Role of splanchnic and renal passage and liver function

  1995cited by this paper
• Mechanisms of disease : endothelins

  1995cited by this paper
• Effect of different endothelin receptor antagonists and of the novel non‐peptide antagonist Ro 46‐2005 on endothelin levels in rat plasma

  1993cited by this paper
• Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.

  1992cited by this paper
• Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis

  1992cited by this paper
• Fully enzymatic inulin determination in small volume samples without deproteinization.

  1992cited by this paper
• Endothelin: an important factor in acute renal failure?

  1988cited by this paper
• A novel potent vasoconstrictor peptide produced by vascular endothelial cells

  1988cited by this paper
• Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis

  1988cited by this paper
• Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function.

  1977cited by this paper
• Measurement of renal function without urine collection. A critical evaluation of the constant-infusion technic for determination of inulin and para-aminohippurate.

  1972cited by this paper

• Endothelin-1 signaling in the kidney: recent advances and remaining gaps.

  2025cites this paper
• Pathophysiology of Hepatorenal Syndrome.

  2024cites this paper
• Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis

  2019cites this paper
• Vascular syndromes in liver cirrhosis

  2019cites this paper
• Hepatorenal syndrome

  2018cites this paper
• Endotoxemia-enhanced renal vascular reactivity to endothelin-1 in cirrhotic rats.

  2018cites this paper
• Promising utilization areas of therapeutic plasmapheresis in cardiovascular surgery practice.

  2018cites this paper
• Hepatorenal Dysfunction in Sepsis: Etiological, Clinical andLaboratory Correlations

  2017influential citation
• Hepatic and Renal Features in Sepsis: Etiological, Clinical and Laboratory Correlations

  2017influential citation
• Pathogenesis of Hepatorenal Syndrome: Implications for Therapy.

  2016cites this paper
• Therapeutic potential of endothelin receptor antagonism in kidney disease.

  2016cites this paper
• Xiayuxue decoction reduces renal injury by promoting macrophage apoptosis in hepatic cirrhotic rats.

  2015cites this paper
• Hepatorenal Disorders.

  2015cites this paper
• Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options

  2015cites this paper
• The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis

  2014cites this paper
• Endothelin receptor antagonists in clinical research--lessons learned from preclinical and clinical kidney studies.

  2014cites this paper
• Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes

  2014cites this paper
• Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis

  2013cites this paper
• Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis.

  2012cites this paper
• Circulating endotoxin and interleukin-6 levels are associated with Doppler-evaluated pulmonary vascular resistance in cirrhotic patients

  2012cites this paper
• Differential Effects of Terlipressin on Pulmonary and Systemic Hemodynamics in Patients With Cirrhosis and Pulmonary Hypertension

  2012cites this paper
• Vasoactive Molecules and the Kidney

  2012cites this paper
• Medical management of hepatorenal syndrome.

  2012cites this paper
• Renal Function Impairment in Patients With Cirrhosis Having Pulmonary Hypertension

  2011cites this paper
• Critical care management of patients with end-stage liver disease

  2011cites this paper
• Renal and circulatory dysfunction in cirrhosis: current management and future perspectives.

  2010cites this paper
• Hepatorenal Syndrome

  2010cites this paper
• Product Code : SMJ 0710 A CME Topic Hepatorenal Syndrome

  2010cites this paper
• Optimal management of hepatorenal syndrome in patients with cirrhosis

  2010cites this paper
• The use of terlipressin in hepatorenal syndrome

  2010cites this paper
• Síndrome hepatorenal: patogénesis y tratamiento

  2010cites this paper
• Complications of Liver Cirrhosis

  2010cites this paper
• Renal failure in cirrhosis.

  2010cites this paper
• Treatment of Hepatorenal Syndrome

  2009cites this paper
• Endothelin-receptor antagonist/N-acetylcysteine combination in type 1 hepatorenal syndrome.

  2009cites this paper
• Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment

  2009influential citation
• Influence of Liver Cirrhosis on the Pharmacokinetics, Pharmacodynamics, and Safety of Tezosentan

  2009cites this paper
• Endothelin-receptor antagonist/N-acetylcysteine combination in type 1 hepatorenal syndrome

  2009cites this paper
• Le syndrome hépatorénal

  2009cites this paper
• Comments on the manuscript "Hepatorenal syndrome: an update"

  2008cites this paper
• The hepatorenal syndrome.

  2008cites this paper
• The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock

  2008cites this paper
• Pathogenetic background for treatment of ascites and hepatorenal syndrome

  2008cites this paper
• Hepatorenal syndrome: Current management

  2008cites this paper
• Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.

  2008cites this paper
• Management of hepatorenal syndrome.

  2008cites this paper
• Significant improvement of portopulmonary hypertension after 1-week terlipressin treatment.

  2008cites this paper